Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Nurix Therapeutics Inc shares valued at $78,931 were sold by van Houte Hans on Nov 03 ’25. At $12.56 per share, van Houte Hans sold 6,284 shares. The insider’s holdings dropped to 37,592 shares worth approximately $0.47 million following the completion of this transaction.
Also, JOHANNES VAN HOUTE purchased 6,284 shares, netting a total of over 81,315 in proceeds.
Before that, van Houte Hans had sold 3,130 shares from its account. In a trade valued at $40,054, the Chief Financial Officer traded Nurix Therapeutics Inc shares for $12.80 each. Upon closing the transaction, the insider’s holdings decreased to 3,130 shares, worth approximately $0.55 million.
As published in their initiating research note from Mizuho on October 21, 2025, Nurix Therapeutics Inc [NRIX] has been an Outperform and the price target has been revised to $24. Analysts at Leerink Partners started covering the stock with ‘”a Market perform”‘ outlook in a report released in mid March. As of December 10, 2024, BTIG Research has initiated its “Buy” rating for NRIX. Earlier on December 06, 2024, BMO Capital Markets initiated its rating. Their recommendation was “an Outperform” for NRIX stock.
Analyzing NRIX Stock Performance
On last trading session, Nurix Therapeutics Inc [NASDAQ: NRIX] rose 1.59% to $12.45. The stock’s lowest price that day was $11.98, but it reached a high of $13.03 in the same session. During the last five days, there has been a surge of approximately 6.45%. Over the course of the year, Nurix Therapeutics Inc shares have dropped approximately -49.10%. Shares of the company reached a 52-week high of $20.66 on 01/27/25 and a 52-week low of $8.18 on 04/10/25.
Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)
According to the 24-hour chart, there is a support level at 11.92, which, if violated, would cause prices to drop to 11.40. In the upper region, resistance lies at 13.00. The next price resistance is at 13.56. RSI (Relative Strength Index) is 64.31 on the 14-day chart, showing neutral technical sentiment.
Is Nurix Therapeutics Inc subject to short interest?
Stocks of Nurix Therapeutics Inc saw a sharp rise in short interest on 2025-10-15 jumping by 0.82 million shares to 13.87 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 13.05 million shares. A jump of 5.93% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.69 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.69.
Which companies own the most shares of Nurix Therapeutics Inc (NRIX)?
In terms of Nurix Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, up nearly 128.38% from the previous closing price of $12.26. Analysts anticipate Nurix Therapeutics Inc stock to reach 33 by 2025, with the lowest price target being 16. In spite of this, 16 analysts ranked Nurix Therapeutics Inc stock as Buy at the end of 2025. On October 24, 2024, UBS assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
